The first generic of Pfizer’s blockbuster erectile dysfunction drug has hit the market. Teva on Monday announced the launch of its Viagra (sildenafil citrate) generic, opening the Jerusalem-based company up to the roughly $1.4 billion market size that IQVIA data shows the drug had for the 12 months ended August 2017.
“The launch of Teva’s sildenafil tablets brings an affordable generic treatment option to the estimated 18 million men in the United States who are diagnosed with erectile dysfunction,” Teva executive vice president of North American commercial Brendan O’Grady said. “Our team has made it a priority to ensure that patients are able to access this medicine—through both traditional and more innovative channels.”
The company was allowed to launch its generic on December 11 as part of a patent infringement settlement it reached with Pfizer in 2013. As part of the settlement, Teva will pay Pfizer a royalty for license to produce the generic.
Teva’s said that it would be offering a savings card that will allow eligible patients to pay as little as $0 out of pocket for the drug, with a maximum benefit of $100 per fill for up to six fills.
December 11, 2017
http://www.drugstorenews.com/
